natgillin/translations-raw huggingface dataset:
Rare: may affect up to 1 in 1,000 people - Severe allergic reactions (anaphylactic reactions, angioedema).
Redki: pojavijo se lahko pri največ 1 od 1000 bolnikov - hude alergične reakcije (anafilaktične reakcije, angioedem).
Trulicity is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
Zdravilo Trulicity je indicirano za zdravljenje odraslih z nezadostno urejeno sladkorno boleznijo tipa 2 kot dopolnilo k dieti in telesni vadbi:
After coadministration with up to 3 mg of dulaglutide at steady state, there were no statistically significant differences on AUC(0-12), Cmax or tmax of paracetamol.
Po sočasnem dajanju dulaglutida do 3 mg v stanju dinamičnega ravnovesja ni bilo klinično pomembnih razlik v AUC(0-12), Cmax ali tmax paracetamola.
Dulaglutide suppresses glucagon secretion which is known to be inappropriately elevated in patients with type 2 diabetes.
Dulaglutid zavira izločanje glukagona, za katerega je znano, da je pri bolnikih s sladkorno boleznijo tipa 2 neprimerno povišan.
The primary endpoint was the time from randomisation to first occurrence of any major adverse cardiovascular events (MACE): CV death, non-fatal myocardial infarction, or non-fatal stroke.
Primarni opazovani dogodek je bil čas od randomizacije do prvega pojava katerega koli večjega kardiovaskularnega neželenega učinka (MACE: KV-smrti, miokardnega infarkta brez smrtnega izida ali možganske kapi brez smrtnega izida.
The results showed that there was no increase in CV risk with dulaglutide compared with control therapies (HR: 0.57; CI: [0.30, 1.10]).
Rezultati kažejo, da ni bilo povečanja kardiovaskularnega tveganja pri dulaglutidu v primerjavi s kontrolnimi zdravljenji (srčni utrip: 0,57; interval zaupanja: [0,30, 1,10]).
Exposures after subcutaneous administration of single dulaglutide (1.5 mg) doses in the abdomen, thigh, or upper arm were comparable.
Izpostavljenosti po subkutani aplikaciji enkratnih odmerkov dulaglutida (1,5 mg) v trebuh, stegno ali nadlaket, so bile primerljive.
How to use Trulicity
Kako uporabljati zdravilo Trulicity
Trulicity 1.5 mg was associated with sustained weight reduction over the duration of studies (from baseline to final time point -0.35 kg to -2.90 kg).
Zdravilo Trulicity 1,5 mg je bilo povezano s trajnim zmanjšanjem telesne mase v času študij (od izhodišča do končne časovne točke 0.35 kg do -2.90 kg).
There was no difference in diastolic blood pressure (DBP).
Pri diastolnem krvnem tlaku ni bilo razlik.
Also contact your local Lilly office listed in the Information for the patient for further instructions.
Prav tako se za nadaljnja navodila obrnite na lokalno podružnico družbe Lilly, navedeno v navodilu za uporabo.
Combination therapy with prandial insulin with or without metformin In this study, patients on 1 or 2 insulin injections per day prior to study entry, discontinued their prestudy insulin regimen and were randomised to dulaglutide once weekly or insulin glargine once daily, both in combination with prandial insulin lispro three times daily, with or without metformin.
Kombinirano zdravljenje s prandialnim insulinom z ali brez metformina V tej študiji so bolniki, ki so pred vstopom v študijo dobivali 1 ali 2 injekciji insulina na dan, prekinili svoj predštudijski insulinski režim in so bili randomizirani v skupino z dulaglutidom enkrat na teden ali v skupino z insulinom glarginom enkrat na dan, obakrat v kombinaciji s prandialnim insulinom lispro trikrat na dan, z ali brez metformina.
In certain situations, for example if you are 75 years or older, your doctor may recommend a starting dose of 0.75 mg once a week.
Če ste starejši od 75 let vam lahko vaš zdravnik priporoči začetni odmerek 0,75 mg enkrat na teden.
Cholelithiasis, cholecystitis
žolčnika in žolčevodov holelitiaza, holecistitis
Pharmacokinetic analyses have demonstrated a statistically significant inverse relationship between body weight or body mass index (BMI) and dulaglutide exposure, although there was no clinically relevant impact of weight or BMI on glycaemic control.
Farmakokinetične analize so pokazale statistično značilno obratno sorazmerje med telesno maso ali indeksom telesne mase (ITM) in izpostavljenostjo dulaglutidu, čeprav ni bilo klinično pomembnega vpliva mase ali ITM na glikemično urejenost.
The time of international normalised ratio response (tINRmax) was delayed by 6 hours, consistent with delays in tmax of approximately 4 and 6 hours for S- and R-warfarin, respectively.
Čas največjega mednarodno umerjenega opaženega odziva INR (tINRmax) se je zakasnil za približno 6 ur, kar je bilo skladno z zakasnitvami tmax za približno 4 in 6 ur za S- in R-varfarin.
Hypoglycaemia* (when used as monotherapy or in combination with metformin plus pioglitazone)
hipoglikemija* (ob uporabi v monoterapiji ali v kombinaciji z metforminom in pioglitazonom)
28 weeks
28 tednov
Changes in body weight with Trulicity 0.75 mg ranged from 0.86 kg to -2.63 kg.
Spremembe v telesni masi za zdravilo Trulicity 0,75 mg so obsegale od 0,86 kg do -2,63 kg.
At the end of the 28 week treatment period the dose was 65 units/day and 51 units/day, for patients receiving placebo and Trulicity 1.5 mg, respectively.
Ob koncu 28-tedenskega obdobja zdravljenja je bil odmerek 65 enot/dan za bolnike, ki so prejemali placebo, oziroma 51 enot/dan za bolnike, ki so prejemali zdravilo Trulicity 1,5 mg.
Many of the reported adverse renal events occurred in patients who had experienced nausea, vomiting, diarrhoea, or dehydration.
Številni neželeni učinki na ledvice, o katerih so poročali, so se pojavili pri bolnikih, pri katerih se je pojavila slabost, bruhanje, driska ali dehidracija.
These effects were not considered to be clinically relevant.
Ti učinki se niso upoštevali za klinično pomembne.
If you use more Trulicity than you should talk to your doctor immediately.
Če ste uporabili večji odmerek zdravila Trulicity, kot bi smeli, morate takoj obvestiti zdravnika.
Too much Trulicity may make your blood sugar too low (hypoglycaemia) and can make you feel sick or be sick.
Zaradi prevelike količine zdravila Trulicity lahko vaš krvni sladkor pade prenizko (hipoglikemija), zaradi česar se lahko slabo počutite oz. vam postane slabo.
If the syringe has been frozen, DO NOT USE.
Če je bila injekcijska brizga zamrznjena, JE NE UPORABITE.
Through the full study duration (up to 104 weeks), the incidence of discontinuation due to adverse events was 5.1% (0.75 mg) and 8.4 % (1.5 mg) for dulaglutide.
V času trajanja celotne študije (do 104 tedne) je bila incidenca prekinitev zaradi neželenih dogodkov 5,1 % (0,75 mg) in 8,4 % (1,5 mg) za dulaglutid.
Especially tell your doctor: - if you are using other medicines that lower the amount of sugar in your blood, such as insulin or a medicine containing sulphonylurea.
- če jemljete druga zdravila, ki zmanjšujejo količino sladkorja v vaši krvi, npr. insulin ali zdravilo, ki vsebuje sulfonilsečnino.
In-use: Trulicity may be stored unrefrigerated for up to 14 days at a temperature not above 30ºC.
Začasno shranjevanje: Zdravilo Trulicity lahko do 14 dni shranjujete zunaj hladilnika, pri temperaturi, ki ne presega 30 ºC.
The safety and efficacy of dulaglutide as add-on to a sulphonylurea was investigated in a placebo controlled study of 24 weeks duration.
Varnost in učinkovitost dulaglutida kot dodatka sulfonilsečnini so preučevali v študiji, nadzorovani s placebom, ki je trajala 24 tednov.
+ Patients randomised to liraglutide were initiated at a dose of 0.6 mg/day.
+ Bolniki, randomizirani v skupino z liraglutidom so zdravljenje začeli z odmerkom 0,6 mg/dan.
The other ingredients are sodium citrate (see section 2 under ‘Trulicity contains sodium citrate' for further information); citric acid, anhydrous; mannitol; polysorbate 80 and water for injections.
Druge sestavine zdravila so natrijev citrat (za več informacij glejte poglavje 2, »Zdravilo Trulicity vsebuje natrijev citrat«), brezvodna citronska kislina, manitol, polisorbat 80 in voda za injekcije.
These changes are not clinically relevant.
Te spremembe niso klinično pomembne.
Do not stop using Trulicity without talking with your doctor.
Ne prenehajte uporabljati zdravila Trulicity, ne da bi se prej posvetovali z zdravnikom.
How can I tell if I have completed my injection?
Kako vem, da je injiciranje končano?
The pharmacokinetics of dulaglutide were evaluated in a clinical pharmacology study and were generally similar between healthy subjects and patients with mild to severe renal impairment (CrCl < 30 ml/min), including end stage renal disease (requiring dialysis).
Farmakokinetika dulaglutida je bila ocenjena v študiji klinične farmakologije in je bila na splošno podobna med zdravimi preiskovanci in bolniki z blago do hudo okvaro delovanja ledvic (CrCl < 30 ml/min), vključno s končno ledvično odpovedjo (bolniki na dializi).
26 weeks
26 tednov
The pharmacokinetics of dulaglutide were evaluated in a clinical pharmacology study, where subjects with hepatic impairment had statistically significant decreases in dulaglutide exposure of up to 30 % to 33 % for mean Cmax and AUC, respectively, compared to healthy controls.
Farmakokinetika dulaglutida je bila ocenjena v študiji klinične farmakologije, kjer so imeli preiskovanci z okvarjenim delovanjem jeter statistično značilna zmanjšanja izpostavljenosti dulaglutidu od 30 % do 33 % za povprečne vrednosti Cmax in AUC v primerjavi z zdravimi preiskovanci.
The initial insulin glargine doses in patients with HbA1c <8.0% were reduced by 20%.
Izhodiščni odmerki insulina glargina pri bolnikih s HbA1c < 8,0% so bili zmanjšani za 20
- Inflamed pancreas (acute pancreatitis) which could cause severe pain in the stomach and back which does not go away.
- Vnetje trebušne slinovke (akutni pankreatitis) kar lahko povzroča hudo bolečino v trebuhu in v hrbtu, ki ne preneha.
When Trulicity is added to existing metformin and/or pioglitazone therapy, the current dose of metformin and/or pioglitazone can be continued.
Če je zdravilo Trulicity dodano obstoječemu zdravljenju z metforminom in/ali pioglitazonom, je mogoče nadaljevati s trenutnim odmerkom metformina in/ali pioglitazona.
A pharmacodynamic study with dulaglutide demonstrated, in patients with type 2 diabetes, a restoration of first phase insulin secretion to a level that exceeded levels observed in healthy subjects on placebo, and improved second phase insulin secretion in response to an intravenous bolus of glucose.
Farmakodinamična študija z dulaglutidom je pri bolnikih s sladkorno boleznijo tipa 2 dokazala obnovo prvostopenjskega izločanja insulina na raven, ki je presegla ravni, opažene pri zdravih preiskovancih, ki so prejemali placebo, ter izboljšala drugostopenjsko izločanje insulina kot odgovor na intravenski bolus glukoze.
- if you are using insulin, your doctor will tell you how to reduce the dose of insulin and will recommend you to monitor your blood sugar more frequently, in order to avoid hyperglycaemia (high blood sugar) and diabetic ketoacidosis (a complication of diabetes that occurs when the body is unable to break down glucose because there is not enough insulin).
- če uporabljate insulin; zdravnik vam bo povedal, kako zmanjšate odmerek insulina, in vam priporočil pogostejše spremljanje sladkorja v krvi, da s tem preprečite pojav hiperglikemije (visoka raven sladkorja v krvi) in diabetične ketoacidoze (zaplet pri sladkorni bolezni, ki nastopi,
≥ 1/1,000 to < 1/100; rare: ≥ 1/10,000 to < 1/1,000; very rare: < 1/10,000 and not known: cannot be estimated from available data).
Neželeni učinki so navedeni v Preglednici 1 po organskih sistemih, kot je priporočeno po MedDRA, in razvrščeni po padajoči incidenci (zelo pogosti: ≥ 1/10; pogosti: ≥ 1/100 do < 1/10; občasni: ≥ 1/1.000 do < 1/100; redki: ≥ 1/10.000 do < 1/1.000; zelo redki: < 1/10.000 in neznano: pogostnosti ni mogoče oceniti na podlagi razpoložljivih podatkov).
When a single dose of dulaglutide and metoprolol were coadministered, the AUC and Cmax of metoprolol increased by19 % and 32 %, respectively.
Ko so sočasno aplicirali po en odmerek dulaglutida in metoprolola, sta se AUC in Cmax metoprolola povečala za 19 % in 32 %.
The recommended dose is 1.5 mg once weekly.
Priporočeni odmerek je 1,5 mg enkrat na teden.
The most frequently reported adverse reactions in clinical trials were gastrointestinal, including nausea, vomiting and diarrhoea.
Neželeni učinki, o katerih so v kliničnih preskušanjih poročali najpogosteje, so bili gastrointestinalni, vključno s slabostjo, bruhanjem in drisko.
Common: may affect up to 1 in 10 people - Hypoglycaemia is common when dulaglutide is used alone, or with both metformin and pioglitazone together, or with a sodium-glucose co-transporter 2 inhibitor (SGLT2i) with or without metformin.
Pogosti: pojavijo se lahko pri največ 1 od 10 bolnikov - hipoglikemija je pogosta bodisi ob uporabi dulaglutida samega, sočasno z metforminom in pioglitazonom ali sočasno z zaviralcem natrijevih glukoznih koprenašalcev 2 (zaviralcem SGLT2) in z metforminom ali brez metformina.
Trulicity is used: - on its own if your blood sugar is not properly controlled by diet and exercise alone, and you can't take metformin (another diabetes medicine).
Zdravilo Trulicity se uporablja: - samostojno, če vaš krvni sladkor ni ustrezno uravnan samo z dieto in telesno vadbo in ne smete jemati metformina (drugo zdravilo za zdravljenje sladkorne bolezni).
Age had no clinically relevant effect on the pharmacokinetic and pharmacodynamic properties of dulaglutide.
Starost ni imela klinično pomembnega učinka na farmakokinetične in famakodinamične lastnosti dulaglutida.
Treatment of rats throughout pregnancy and lactation produced memory deficits in female offspring at exposures that were 16-fold higher than those proposed clinically.
Odmerjanje dulaglutida ves čas brejosti in laktacije podgan je povzročilo okvare spomina pri mladičih ženskega spola pri 16-kratniku izpostavljenosti človeka pri predlagani klinični uporabi.
Combination therapy with metformin
Kombinirano zdravljenje z metforminom
- Hypoglycaemia (low blood sugar) is very common when dulaglutide is used with medicines that contain metformin, a sulphonylurea and/or insulin.
- hipoglikemija (nizek krvni sladkor) je zelo pogosta ob sočasni uporabi dulaglutida z zdravili, ki vsebujejo metformin, sulfonilsečnino in/ali insulin.
If you forget to use Trulicity
Če ste pozabili vzeti zdravilo Trulicity
There were significantly fewer patients in the Trulicity group who received an additional glycaemic intervention compared to placebo (Trulicity: 2,086 [42.2 %]; placebo: 2,825 [57.0 %]; p < 0.001).
V primerjavi s skupino, ki je prejemala placebo, je pomembno manj bolnikov v skupini, ki je prejemala zdravilo Trulicity, prejelo dodatno intervencijsko zdravilo za nadzor glikemije (zdravilo Trulicity: 2086 [42,2 %]; placebo: 2825 [57,0 %]; p < 0,001).
In studies of 26 weeks duration, the incidence of discontinuation due to adverse events was 2.6% (0.75 mg) and 6.1% (1.5 mg) for dulaglutide versus 3.7 % for placebo.
V študijah, ki so trajale 26 tednov, je bila incidenca prekinitev zaradi neželenih dogodkov 2,6 % (0,75 mg) in 6,1% (1,5 mg) za dulaglutid v primerjavi s 3,7 % za placebo.
INFORMATION IN BRAILLE TRULICITY 0.75 mg
PODATKI V BRAILLOVI PISAVI TRULICITY 0,75 mg
In the same study, a single 1.5 mg dose of dulaglutide appeared to increase maximal insulin secretion from the β-cells, and to enhance β-cell function in subjects with type 2 diabetes mellitus as compared with placebo.
V isti študiji je enkratni odmerek dulaglutida 1,5 mg povečal največje izločanje insulina iz β-celic ter povečal delovanje β-celic pri preskušancih s sladkorno boleznijo tipa 2 v primerjavi s placebom.
In a meta-analysis of phase II and III registration studies, a total of 51 patients (dulaglutide: 26 [N = 3,885]; all comparators: 25 [N = 2,125]) experienced at least one cardiovascular (CV) event (death due to CV causes, nonfatal MI, nonfatal stroke, or hospitalisation for unstable angina).
V metaanalizi registracijskih študij 2. in 3. faze je skupno 51 bolnikov (dulaglutid: 26 [N = 3885]; vsa primerjalna zdravila: 25 [N = 2125]) doživelo vsaj en kardiovaskularni (KV) dogodek (smrt zaradi KV
These studies included 3,808 dulaglutide treated patients, of whom 2,250 were treated with Trulicity 1.5 mg weekly and 1,558 were treated with Trulicity 0.75 mg weekly.
Te študije so vključevale 3808 bolnikov, zdravljenih z dulaglutidom, od katerih je bilo 2250 bolnikov tedensko zdravljenih z zdravilom Trulicity 1,5 mg, 1558 pa jih je bilo tedensko zdravljenih z zdravilom Trulicity 0,75 mg.
None of the patients with systemic hypersensitivity developed dulaglutide anti-drug antibodies.
Pri nobenem od bolnikov s sistemsko preobčutljivostjo se niso razvila protitelesa proti dulaglutidu.
Trulicity has no or negligible influence on the ability to drive or use machines.
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Zdravilo Trulicity nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
2 PLACE AND UNLOCK
2 NAMESTITE IN ODKLENITE
If the injection is given by someone else, they may inject in your upper arm.
Če vam injekcijo da druga oseba, vam zdravilo lahko injicira v vašo nadlaket.
You should receive training from your doctor, pharmacist or nurse on the right way to prepare and inject your medicine.
Zdravnik, farmacevt ali medicinska sestra vas bodo ustrezno poučili o pravilnem načinu priprave in injiciranja zdravila.
However, no trend in dulaglutide exposure was observed relative to the degree of hepatic impairment.
Kljub temu niso opazili trenda izpostavljenosti dulaglutidu glede na stopnjo okvarjenosti jetrnega delovanja.
* Documented, symptomatic hypoglycaemia with blood glucose ≤ 3.9 mmol/L † Dulaglutide 1.5 mg dose only.
* Dokumentirana simptomatska hipoglikemija s krvno glukozo ≤ 3,9 mmol/l.
If less than 3 days (72 hours) remain before the next scheduled dose, the missed dose should be skipped and the next dose should be administered on the regularly scheduled day.
Če so do naslednjega predpisanega odmerka ostali manj kot 3 dnevi (72 ur), je treba zamujeni odmerek preskočiti, naslednji odmerek pa dati na naslednji predpisani dan.
The safety and efficacy of dulaglutide was also investigated in an active controlled study (liraglutide 1.8 mg daily) of 26 weeks duration, both in combination with metformin.
Varnost in učinkovitost dulaglutida so preučevali tudi študiji, nadzorovani z aktivno primerjavo (liraglutid 1,8 mg na dan), ki je trajala 26 tednov, obakrat v kombinaciji z metforminom.
Additionally, in a 52-week clinical study in patients with type 2 diabetes and moderate to severe renal impairment (eGFR [by CKD-EPI] <60 and ≥15 mL/min/1.73 m2), the pharmacokinetic profile of Trulicity 0.75 mg and 1.5 mg once weekly was similar to that demonstrated in previous clinical studies.
Poleg tega je bil v 52-tedenski klinični študiji, ki je vključila bolnike s sladkorno boleznijo tipa 2 in z zmerno do hudo okvaro delovanja ledvic (eGFR [po CKDEPI] < 60 in ≥ 15 ml/min/1,73 m2) farmakokinetični profil zdravila Trulicity 0,75 mg in 1,5 mg, danega enkrat na teden, podoben tistemu, ki so ga dokazali v predhodnih kliničnih študijah.
The safety and efficacy of dulaglutide was investigated in a placebo and active controlled (sitagliptin 100 mg daily) study of 104 weeks duration, all in combination with metformin.
Varnost in učinkovitost zdravila Trulicity sta bili raziskani v študiji, nadzorovani s placebom in aktivno primerjavo (sitagliptin 100 mg na dan), ki je trajala 104 tedne, vedno v kombinaciji z metforminom.
Dulaglutide delays gastric emptying and has the potential to impact the rate of absorption of concomitantly administered oral medicinal products.
Dulaglutid zakasni praznjenje želodca in lahko vpliva na hitrost absorpcije sočasno vzetih peroralnih zdravil.
• Inject your dose using another syringe.
• Svoj odmerek si injicirajte z drugo injekcijsko brizgo.
It is important to avoid dehydration by drinking plenty of fluids.
Pomembno je, da pijete veliko tekočine in se tako izognete dehidraciji.
If the pen has been frozen, DO NOT USE.
Če je bil peresnik zamrznjen, GA NE UPORABITE.
Dulaglutide coadministration with sitagliptin increased dulaglutide exposure and Cmax by approximately 38 % and 27 %, respectively, and median tmax increased approximately 24 hours.
Sočasno dajanje dulaglutida in sitagliptina je povečalo izpostavljenost dulaglutidu in Cmax za približno 38 % in 27 %, mediani tmax pa je naraščal v obdobju približno 24 ur.
There was a general increase in tmax of dulaglutide with increased hepatic impairment.
Opazili so tudi splošno povečanje časa tmax dulaglutida ob povečani okvari delovanja jeter.
No dosage adjustment is required in patients with mild, moderate or severe renal impairment (eGFR <90 to ≥15 mL/min/1.73m2).
Pri bolnikih z blago, zmerno ali hudo okvarjenim delovanjem ledvic (eGFR < 90 do ≥ 15 ml/min/1,73m2) prilagoditev odmerka ni potrebna.
Do not use this medicine after the expiry date which is stated on the pen label and on the carton after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na oznaki peresnika in na škatli poleg oznake „Uporabno do/EXP“.
When Trulicity is added to existing metformin and/or sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy, the current dose of metformin and/or SGLT2i can be continued.
Če je zdravilo Trulicity dodano obstoječemu zdravljenju z metforminom in/ali zaviralcem natrijevih glukoznih koprenašalcev 2 (SGLT2), je mogoče nadaljevati s trenutnim odmerkom metformina in/ali zaviralca SGLT2.
Glass syringe (type I) encased in a disposable pen.
Steklena brizga (tip I) je vložena v peresnik za enkratno uporabo.
It should not be administered intravenously or intramuscularly.
Zdravila Trulicity se ne sme aplicirati intravensko ali intramuskularno.
Do not put the needle cover back on - this may result in an accidental needle stick injury to your hand.
• Ne nameščajte znova pokrovčka igle - to bi lahko povzročilo poškodbo vaše dlani zaradi vboda z iglo.
- you are taking a sulphonylurea or insulin for your diabetes, as low blood sugar (hypoglycaemia) can occur.
- jemljete sulfonilsečnino ali insulin za zdravljenje vaše sladkorne bolezni, saj lahko pride do nizkega krvnega sladkorja (hipoglikemija).
Following coadministration with 2 consecutive doses of dulaglutide, sitagliptin AUC(0-τ) and Cmax decreased by approximately 7.4 % and 23.1 %, respectively.
Po sočasnem dajanju z dvema zaporednima odmerkoma dulaglutida sta se AUC(0-τ) in Cmax sitagliptina zmanjšala za približno 7,4 % in 23,1 %.
Following a first dose of 1 and 3 mg dulaglutide, paracetamol Cmax was reduced by 36 % and 50 %, respectively, and the median tmax occurred later (3 and 4 hours, respectively).
Po prvem odmerku 1 in 3 mg dulaglutida se je največja koncentracija Cmax paracetamola znižala za 36 % in 50 %, mediana časa do maksimalne serumske koncentracije tmax pa je nastopila pozneje (3 in 4 ure pozneje).
Storage and Handling Disposal of Pen Commonly Asked Questions Other Information Where to Learn More
Shranjevanje in rokovanje Odlaganje peresnika Pogosto zastavljena vprašanja Druge informacije
In addition, there was significantly lower perceived frequency of hyperglycaemia and hypoglycaemia compared to exenatide twice daily.
Poleg tega so bolniki navedli značilno nižjo zaznano pogostnost hiperglikemije in hipoglikemije v primerjavi z eksenatidom dvakrat na dan.
Patients at target HbA1c
Bolniki, ki so dosegli ciljno vrednost HbA1c
Sitagliptin tmax increased approximately 0.5 hours following coadministration with dulaglutide compared to sitagliptin alone.
tmax sitagliptina se je povečal približno 0,5 ure po sočasnem dajanju dulaglutida v primerjavi z dajanjem samega sitagliptina.
Place the clear base flat and firmly against your skin at the injection site.
• Prozorno podnožje plosko in trdno namestite na kožo na mestu injiciranja.
INFORMATION IN BRAILLE TRULICITY 1.5 mg
PODATKI V BRAILLOVI PISAVI TRULICITY 1,5 mg